Drilldown: Medicines

Other values:

Search

None (15) · (none, never marketed) (1) · Adderall, Adderall XR, Mydayis (1) · Captagon (1) · Dalmane (1) · Desoxyn (1) · Dexedrine (1) · Doral (1) · Doriden (1) · Halcion (1) · Hetlioz (1) · Imovane (1) · Lunesta (1) · Mogadon (1) · Nembutal (1) · Placidyl (1) · ProSom (1) · Quaalude (1) · Restoril (1) · Rohypnol (1) · Rozerem (1) · Seconal (1) · Sonata (1) · THIP (1) · Versed (1) · Xyrem (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (2) · Extremely potent GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator (15) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · GABAA positive allosteric modulator; very long half-life (1) · GABAA potentiator (1) · GABAA potentiator and direct activator (2) · GABAB agonist; GHB receptor agonist (1) · Melatonin receptor agonist (2) · Monoamine releasing agent (6) · Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Positive allosteric modulator of the GABA_A receptor at the benzodiazepine binding site; increases frequency of Cl⁻ channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) · Prodrug of amphetamine + theophylline (1) · Selective GABAA agonist (extrasynaptic delta subunit) (1) · TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1)

None (37) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) · '"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)

None (37) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 5 mg PO (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (37) · Desoxyn 5 mg tabs (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1)

None (37) · 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) · N/A (never approved) (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

None (37) · intranasal; rectal and IV reported. (1) · Oral (2) · Oral (prescribed) (1) · sublingual (1)

None (38) · IR: 30–60 min; XR: 1–2 h to peak effect (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (38) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1)

None (38) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1)

None (38) · Not formally characterized in humans. (1) · ~75–90% (oral) (1)

None (37) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Category C (1) · Category C (per Desoxyn label) (1)

None (38) · Schedule II (2)